ID   N6-1000
AC   CVCL_UJ07
DR   cancercelllines; CVCL_UJ07
DR   Wikidata; Q95991925
RX   PubMed=1370437;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16).
CC   Sequence variation: Gene fusion; HGNC; 50800; DUX4 + HGNC; 5477; IGH; Name(s)=IGH-DUX4; Note=The translocation occurs in the silenced IGH allele (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9143; Adult B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0092 ! NALM-6
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 30-01-24; Version: 11
//
RX   PubMed=1370437; DOI=10.1002/ijc.2910500223;
RA   Treichel R.S., Olken S.;
RT   "The relationship between multi-drug resistance and resistance to
RT   natural-killer-cell and lymphokine-activated killer-cell lysis in
RT   human leukemic cell lines.";
RL   Int. J. Cancer 50:305-310(1992).
//